| Value | ₹44.78 Cr |
|---|
BSE filing, BSE: 544529. Summary written from the filing by ALFA Finder's alert engine.
Aptus Pharma Ltd: key numbers
- Share price
- ₹462.50
- Market cap
- ₹793.2 Cr
- Revenue (annual)
- ₹46.57 Cr
- Net profit (annual)
- ₹4.62 Cr
- P/E (TTM)
- 171.7×Sector 48.7×
- Promoter holding
- 72.89%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aptus Pharma Ltd
All →Aptus Pharma Investor Presentation: Key Takeaways
H1 FY27 revenue ₹48.92 Cr, EBITDA ₹7.68 Cr (15.7% margin), PAT ₹5.07 Cr; revenue exceeds full FY26 (₹46.57 Cr). Trading-heavy model with rising receivables and negative operating cash flow.
Aptus Pharma H1 FY27 Results: Net Profit ₹5.1 Cr, Up 200.0% YoY
Aptus Pharma Ltd reported revenue from operations of ₹48.9 Cr (+239.6% YoY) and net profit of ₹5.1 Cr (+200.0% YoY) for H1 FY27.
- Key figure
- Net profit ₹5.1 Cr · +200.0% YoY
Aptus Pharma Other Announcement
Aptus Pharma Limited submitted the Regulation 74(5) compliance certificate for the quarter and half-year ended 30th September 2026, as received from its registrar.
Aptus Pharma Annual General Meeting
Aptus Pharma Ltd issued a corrigendum to its 16th AGM notice regarding inadvertent errors in the explanatory statement for item no. 3.
Aptus Pharma Fund Raise of ₹44.88 Cr
Aptus Pharma Limited's Board has approved raising ₹44.88 Crore through a preferential equity issue. Funds will support manufacturing capacity expansion, working capital, and Pan-India growth initiatives.
- Value
- ₹44.88 Cr
- Execution
- 36 months
Aptus Pharma Annual Report
Aptus Pharma has filed its Annual Report for FY 2025-26 with the exchange. The report includes the notice for the upcoming 16th Annual General Meeting.
Other preferential issue announcements
All →Taurian Mps Preferential Issue
Taurian MPS allotted 2,31,200 equity shares and 8,48,800 convertible warrants at Rs 419 each on preferential basis. Upfront consideration totals Rs 18.58 Crore, with warrant balances payable on conversion.
- Value
- ₹18.58 Cr
Emrock Corporation Preferential Issue
Emrock allotted 55 lakh equity shares at Rs 11 each to eight investors via preferential issue. The allotment raises Rs 6.05 Crore.
- Value
- ₹6.05 Cr
Bizotic Commercial Preferential Issue
Bizotic Commercial corrected its EGM notice, revising the Rs 146.41 Crore preferential warrant issue. Members may re-vote on that item until 2 November 2026.
- Value
- ₹146.4 Cr
Kross Preferential Issue
Kross allotted 15 lakh preferential shares at Rs 212 to non-promoters, plus 15 lakh convertible warrants to promoters. Combined value totals Rs 63.60 Crore.
- Value
- ₹63.60 Cr
- Execution
- Warrants convertible into equity shares within 18 months from the date of allotment
Dhariwalcorp Preferential Issue
Dhariwalcorp's EGM approved the issue of 33,00,000 equity shares to the promoter on preferential basis. The proposed 1,70,01,000 convertible warrants were not approved.
Milkfood Preferential Issue
Milkfood Ltd allotted 1,100,000 shares each to Director Sudhir Avasthi and Deepankar Barat in a preferential issue. Total consideration was ₹6.60 Crore.
- Value
- ₹6.60 Cr